ASE Joins Letter in Support of National Coverage Determination for TTVR

On January 17, ASE joined a coalition of cardiovascular groups in a comment letter to CMS applauding their proposed decision to enlist Medicare coverage of transcatheter tricuspid value replacements (TTVR) under coverage with evidence development (CED). The comments acknowledge the novel approach CMS is taking that requires the trial sponsor to lead the delivery of a breakthrough device. The societies offer recommendations on best practices to carry out CMS’ goals outlined in the proposed decision.